39 results on '"Trinkaus, Kathryn"'
Search Results
2. Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients
3. Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience
4. Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation
5. Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation
6. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
7. Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated
8. Improved in vivo diffusion tensor imaging of human cervical spinal cord
9. Factors associated with attaining coaching goals during an intervention to improve child asthma care
10. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
11. Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords
12. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
13. A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation
14. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation
15. Impact of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma
16. A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
17. 451 - T-Cell Replete Peripheral Blood Haploidentical Donor Transplant is Frequently Associated with Cytokine Release Syndrome Which Responds to IL-6 Inhibition—Updated Outcomes Data with Longer Follow-Up
18. Pretransplant Clinical Factors Can be Used to Predict the Risk of Cytokine Release Syndrome after Haploidentical Peripheral Blood Transplantation
19. Ultra-Deep Sequencing As a Predictive Tool for MDS Progression after Allogeneic Hematopoietic Cell Transplant
20. 128 - Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation
21. Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation
22. Geriatric Assessment in Older Adults with Multiple Myeloma
23. Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant
24. Distinct Clinical, Laboratory, and Molecular Features of Myeloproliferative Neoplasm Patients Presenting with Splanchnic Vein Thrombosis
25. Phase I Study of Brentuximab Vedotin for the Prevention of Acute GvHD after Unrelated Allogeneic Stem Cell Transplantation
26. T-Cell-Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Active Disease AML and MDS Leads to Outcomes Similar to Matched Related and Unrelated Donor Transplantation
27. Comparable Survival with HLA Haploidentical and Mismatched Unrelated Donor Transplants in Patients with AML and MDS
28. Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma
29. T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy
30. Transplant Outcomes in Older Patients Are Comparable to Outcomes in Younger Patients after Hopkin's Non-Myeloablative Flu Cy TBI + PT-Cy Regimen
31. Sargramostim (GM-CSF) Combined with IV Plerixafor to Mobilize Peripheral Blood Stem Cells (PBSC) from Normal HLA-Matched Allogeneic Sibling Donors
32. Relation of Age, Severity of Illness, and Hemodynamics With Brain Natriuretic Peptide Levels in Patients
33. A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
34. 532 DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL OF OXYBUTYNIN EXTENDED RELEASE VS. PLACEBO FOR URINARY SYMPTOMS DURING TREATMENT WITH INTRAVESICAL BACILLUS CALMETTE-GUÉRIN
35. Outcomes of Patients Receiving Allogeneic Peripheral Blood Stem Cell Products Mobilized with Intravenous Plerixafor
36. A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.
37. A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results
38. Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.
39. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.